1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Duchenne Muscular Dystrophy Drugs Market
2.2. Global Duchenne Muscular Dystrophy Drugs Market, By Drug Type, 2024 (US$ Million)
2.3. Global Duchenne Muscular Dystrophy Drugs Market, By Route of Administration, 2024 (US$ Million)
2.4. Global Duchenne Muscular Dystrophy Drugs Market, By Geography, 2024 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2024

3. Duchenne Muscular Dystrophy Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Duchenne Muscular Dystrophy Drugs Market Vendors
3.2. Strategies Adopted by Duchenne Muscular Dystrophy Drugs Market Vendors
3.3. Key Industry Strategies

4. Duchenne Muscular Dystrophy Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Duchenne Muscular Dystrophy Drugs Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Exon skipping drugs
5.3.2. Corticosteroids
5.3.3. Gene therapy
5.3.4. Other drug types

6. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2024 Versus 2033
6.3. Market Segmentation
6.3.1. Oral
6.3.2. Injectable


7. North America Duchenne Muscular Dystrophy Drugs Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
7.3. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
7.4.Duchenne Muscular Dystrophy Drugs Market: By Region, 2023-2033, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
7.4.1.1.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
7.4.1.2.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
7.4.1.3.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)

8. UK and European Union Duchenne Muscular Dystrophy Drugs Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.3. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.Duchenne Muscular Dystrophy Drugs Market: By Region, 2023-2033, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.1.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.2.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.3.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.4.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.1.5. France
8.4.1.5.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.5.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
8.4.1.6.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)

9. Asia Pacific Duchenne Muscular Dystrophy Drugs Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.3. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.Duchenne Muscular Dystrophy Drugs Market: By Region, 2023-2033, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.1.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.2.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.1.3. India
9.4.1.3.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.3.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.4.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.5.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
9.4.1.6.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)

10. Latin America Duchenne Muscular Dystrophy Drugs Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
10.3. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
10.4.Duchenne Muscular Dystrophy Drugs Market: By Region, 2023-2033, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
10.4.1.1.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
10.4.1.2.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
10.4.1.3.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)

11. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market, 2023-2033, USD (Million)
11.1. Market Overview
11.2. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
11.3. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
11.4.Duchenne Muscular Dystrophy Drugs Market: By Region, 2023-2033, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
11.4.1.1.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
11.4.1.2.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Duchenne Muscular Dystrophy Drugs Market: By Drug Type, 2023-2033, USD (Million)
11.4.1.3.2. Duchenne Muscular Dystrophy Drugs Market: By Route of Administration, 2023-2033, USD (Million)

12. Company Profile
12.1. Capricor Therapeutics, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. FibroGen, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Catalyst Pharmaceuticals Inc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Aurobindo Pharma
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. EspeRare Foundation
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Italfarmaco S.p.A
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. NS Pharma
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. PTC Therapeutics, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Pfizer Inc
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Santhera Pharmaceuticals
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Sarepta Therapeutics, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Solid Biosciences Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives